COVID-19 大流行期间，囊性纤维化幼儿肺部恶化减少。
Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic.
机构信息
Indiana University School of Medicine, Indianapolis, Indiana, USA.
Division of Pediatric Pulmonology, Allergy, and Sleep Medicine, Riley Hospital for Children, Indianapolis, Indiana, USA.
出版信息
Pediatr Pulmonol. 2021 May;56(5):1271-1273. doi: 10.1002/ppul.25250. Epub 2021 Jan 12.
Abstract
To assess the impact of COVID-19 restrictions on cystic fibrosis (CF) pulmonary exacerbations (PEx) we performed a retrospective review of PEx events at our CF Center and compared the rate of PEx in 2019 versus 2020. Restrictions on social interaction due to the COVID-19 pandemic were associated with a lower number of PEx events at our pediatric CF Center, suggesting that these restrictions also reduced exposure to other respiratory viral infection in children with CF.
摘要
为了评估 COVID-19 限制措施对囊性纤维化（CF）肺部恶化（PEx）的影响，我们对我院 CF 中心的 PEx 事件进行了回顾性分析，并比较了 2019 年和 2020 年的 PEx 发生率。由于 COVID-19 大流行而对社会互动的限制与我院儿科 CF 中心的 PEx 事件数量减少有关，这表明这些限制措施还减少了 CF 患儿接触其他呼吸道病毒感染的机会。
相似文献
1
Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic.COVID-19 大流行期间，囊性纤维化幼儿肺部恶化减少。
Pediatr Pulmonol. 2021 May;56(5):1271-1273. doi: 10.1002/ppul.25250. Epub 2021 Jan 12.
2
Effect of the COVID-19 pandemic on anxiety among children with cystic fibrosis and their mothers.新冠疫情对囊性纤维化患儿及其母亲焦虑情绪的影响。
Pediatr Pulmonol. 2020 Aug;55(8):2128-2134. doi: 10.1002/ppul.24900. Epub 2020 Jun 26.
3
Aetiological agents for pulmonary exacerbations in children with cystic fibrosis: An observational study from a tertiary care centre in northern India.印度北部一家三级护理中心的观察性研究：囊性纤维化患儿肺部加重的病因。
Indian J Med Res. 2020 Jan;151(1):65-70. doi: 10.4103/ijmr.IJMR_1275_18.
4
Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.纵向队列研究中婴幼儿囊性纤维化患者肺部加重与临床结局的关系。
BMC Pulm Med. 2017 Dec 11;17(1):188. doi: 10.1186/s12890-017-0546-8.
5
Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.全身性皮质类固醇在儿童囊性纤维化肺部加重期治疗中的应用
Ann Am Thorac Soc. 2023 Jan;20(1):75-82. doi: 10.1513/AnnalsATS.202203-201OC.
6
Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic.系统评价：严重急性呼吸综合征冠状病毒 2 型/COVID-19 大流行中的囊性纤维化。
BMC Pulm Med. 2021 May 20;21(1):173. doi: 10.1186/s12890-021-01528-0.
7
Poor Respiratory Health Following Relapsing SARS-CoV-2 Infection in Children with Cystic Fibrosis.儿童囊性纤维化患者复发 SARS-CoV-2 感染后呼吸健康状况较差。
Indian J Pediatr. 2022 Apr;89(4):404-406. doi: 10.1007/s12098-021-04057-0. Epub 2022 Jan 28.
8
Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.影响囊性纤维化患者下次肺部病情加重时间的治疗及人口统计学因素。
J Cyst Fibros. 2015 Nov;14(6):763-9. doi: 10.1016/j.jcf.2015.02.007. Epub 2015 Mar 6.
9
Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey.西班牙囊性纤维化患者中 SARS-CoV-2 感染的影响：全国 CF-COVID19-西班牙调查的发病率和结果。
Respir Med. 2020 Aug-Sep;170:106062. doi: 10.1016/j.rmed.2020.106062. Epub 2020 Jun 8.
10
Clinical features associated with pulmonary exacerbation diagnosis in infants and young children with cystic fibrosis.囊性纤维化婴幼儿肺部恶化诊断相关的临床特征。
Pediatr Pulmonol. 2024 Apr;59(4):874-879. doi: 10.1002/ppul.26838. Epub 2023 Dec 22.
引用本文的文献
1
Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.依伐卡托-替扎卡托-艾列卡托、替扎卡托-依伐卡托和鲁玛卡托-依伐卡托治疗囊性纤维化：系统评价与经济学评估
Health Technol Assess. 2025 May;29(19):1-111. doi: 10.3310/CPLD8546.
2
Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis.依列卡福妥/替扎卡福妥/依伐卡托对青少年和成人囊性纤维化患者疾病负担的真实世界疗效。
Heliyon. 2024 Mar 26;10(7):e28508. doi: 10.1016/j.heliyon.2024.e28508. eCollection 2024 Apr 15.
3
Bronchiectasis and COVID-19: For Better or for Worse?支气管扩张症与2019冠状病毒病：是福是祸？
Ann Am Thorac Soc. 2024 Feb;21(2):208-210. doi: 10.1513/AnnalsATS.202312-1018ED.
4
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one allele: 144-week interim results from a 192-week open-label extension study.在至少携带一个 F508del 等位基因的囊性纤维化患者中，elexacaftor/tezacaftor/ivacaftor 的长期安全性和疗效：一项为期 192 周的开放标签扩展研究的 144 周中期结果。
Eur Respir J. 2023 Dec 7;62(6). doi: 10.1183/13993003.02029-2022. Print 2023 Dec.
5
Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis.高效CFTR调节剂疗法对囊性纤维化患儿的实际影响。
Front Pharmacol. 2023 May 9;14:1176815. doi: 10.3389/fphar.2023.1176815. eCollection 2023.
6
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One Allele: A Phase 3, Open-Label Clinical Trial.Elexacaftor/Tezacaftor/Ivacaftor 在至少有一个等位基因的 ⩾6 岁囊性纤维化儿童中的长期安全性和疗效：一项 3 期、开放标签临床试验。
Am J Respir Crit Care Med. 2023 Jul 1;208(1):68-78. doi: 10.1164/rccm.202301-0021OC.
7
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One Allele.Elexacaftor/Tezacaftor/Ivacaftor 治疗囊性纤维化患儿的 2-5 岁儿童期开放标签 3 期临床试验，至少有一个等位基因。
Am J Respir Crit Care Med. 2023 Jul 1;208(1):59-67. doi: 10.1164/rccm.202301-0084OC.
8
Management of respiratory tract exacerbations in people with cystic fibrosis: Focus on imaging.囊性纤维化患者呼吸道加重的管理：聚焦于影像学
Front Pediatr. 2023 Feb 6;10:1084313. doi: 10.3389/fped.2022.1084313. eCollection 2022.
9
Is cystic fibrosis a risk factor for COVID-19 infection or related complications?囊性纤维化是新型冠状病毒肺炎感染或相关并发症的危险因素吗？
J Bras Pneumol. 2023 Jan 13;48(6):e20220445. doi: 10.36416/1806-3756/e20220445.
10
Clinical outcomes of adults and children with cystic fibrosis during the COVID-19 pandemic.COVID-19 大流行期间囊性纤维化成人和儿童的临床结局。
J Cyst Fibros. 2023 May;22(3):581-586. doi: 10.1016/j.jcf.2022.09.006. Epub 2022 Sep 16.
本文引用的文献
1
Clinical impact of respiratory virus in pulmonary exacerbations of children with Cystic Fibrosis.呼吸道病毒对囊性纤维化患儿肺部加重的临床影响。
PLoS One. 2020 Oct 28;15(10):e0240452. doi: 10.1371/journal.pone.0240452. eCollection 2020.
2
COVID-19 public health measures and respiratory syncytial virus.新冠疫情公共卫生措施与呼吸道合胞病毒
Lancet Child Adolesc Health. 2020 Nov;4(11):e42-e43. doi: 10.1016/S2352-4642(20)30307-2. Epub 2020 Sep 18.
3
Decreased Influenza Activity During the COVID-19 Pandemic - United States, Australia, Chile, and South Africa, 2020.新冠疫情期间流感活动减少——美国、澳大利亚、智利和南非，2020 年。
MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1305-1309. doi: 10.15585/mmwr.mm6937a6.
4
Disease Control, Civil Liberties, and Mass Testing - Calibrating Restrictions during the Covid-19 Pandemic.疾病控制、公民自由与大规模检测——新冠疫情期间的限制措施校准
N Engl J Med. 2020 Jul 9;383(2):102-104. doi: 10.1056/NEJMp2007637. Epub 2020 Apr 9.
5
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
6
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
7
Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial.吸入高渗盐水在婴儿和 6 岁以下囊性纤维化儿童中的应用：ISIS 随机对照试验。
JAMA. 2012 Jun 6;307(21):2269-77. doi: 10.1001/jama.2012.5214.
8
The role of respiratory viruses in cystic fibrosis.呼吸道病毒在囊性纤维化中的作用。
J Cyst Fibros. 2008 Jul;7(4):320-328. doi: 10.1016/j.jcf.2007.12.002. Epub 2008 Feb 6.
Zotero 插件